CARMAX REPORTS FIRST QUARTER FISCAL YEAR 2026 RESULTS Richmond, Va., June 20, 2025 – CarMax, Inc. (NYSE:KMX) today reported results for the first quarter ended May 31, 2025. First Quarter Highlights: (1) • Net earnings per diluted share increased 42.3% to $1.38 from $0.97 a year ago. • Retail used unit sales increased 9.0% and comparable store used unit sales increased 8.1%; wholesale units increased 1.2%. • Total gross profit increased 12.8% to $893.6 million, driven by higher unit volumes and strong unit ...

Company Overview - Medtronic serves over 95,000 patients and operates in more than 150 countries, with a research and development spend of $2.7 billion[18]. - The company has over 95,000 full-time employees, with 44% based in the U.S. or Puerto Rico[39]. - The company's principal executive office is located in Ireland, while its main operational offices are in Minneapolis, Minnesota[167]. Innovation and Product Development - The company aims to accelerate innovation-driven growth through recent product launches and a robust pipeline, targeting strong revenue growth in attractive end markets[20]. - Medtronic's diverse product offerings across multiple portfolios position it well for future market expansion and innovation[19]. - The company is committed to maintaining technological leadership through extensive R&D efforts, participating in hundreds of clinical trials each fiscal year[51]. - The company emphasizes the integration of data, AI, and automation to improve patient care and operational efficiency[20]. - The company continues to support patients with HVAD devices despite halting the distribution of the HVAD System in June 2021[22]. Financial Performance - For fiscal year 2025, the company reported net income attributable to Medtronic of $4,662 million, with diluted EPS of $3.61 and an effective tax rate of 16.6%[191]. - Non-GAAP net income for fiscal year 2025 was $7,079 million, with diluted EPS of $5.49 and a non-GAAP effective tax rate of 16.7%[191]. - Free cash flow for fiscal year 2025 was $5,185 million, compared to $5,200 million in fiscal year 2024[194]. - Total net sales for fiscal year 2025 increased by 4% to $33,537 million, driven by growth in several segments including Cardiac Rhythm & Heart Failure and Diabetes[199]. Market Segments - Medtronic's Cardiovascular Portfolio includes advanced products such as implantable cardiac pacemakers and defibrillators, contributing significantly to its revenue streams[21][22]. - The Structural Heart & Aortic division offers therapies for heart valve disorders and aortic disease, enhancing the company's treatment capabilities[23]. - The Neuroscience Portfolio includes products for spinal and cranial technologies, addressing a wide range of neurological conditions[25]. - Medtronic's Medical Surgical Portfolio focuses on advanced surgical products and therapies, catering to healthcare systems and alternate site providers[32]. Regulatory Environment - The global regulatory environment is increasingly stringent, impacting the cost and time needed for product approvals[67]. - The EU Medical Device Regulation (EU MDR) became effective on May 26, 2021, with an extended implementation period for high-risk devices until the end of 2027[66]. - Compliance with evolving data privacy and cybersecurity regulations has resulted in increased costs and compliance challenges[70]. - Regulatory compliance is complex and any adverse actions from agencies like the U.S. FDA could materially affect the company's operations and market position[99]. Competition and Market Challenges - The company faces competition from both large manufacturers and small companies, as well as pharmaceutical companies producing alternative therapies[58]. - The healthcare industry consolidation and the rise of ambulatory surgery centers (ASCs) could lead to increased competition and downward pricing pressure on the company's products[156][158]. - Cost-containment measures in the healthcare industry may result in reduced sales of medical devices, as third-party payors may deny payment approvals for procedures involving the company's products[159]. Supply Chain and Operational Risks - Supply chain disruptions, particularly for components like semiconductors, have previously affected manufacturing operations[86]. - The company faces risks related to supply chain disruptions, including reliance on petroleum-based materials, which can significantly affect manufacturing costs and sales[88]. - The company has plans in place to ensure continuity of supply for components and raw materials, despite potential regulatory challenges[62]. Corporate Social Responsibility - The company has a strong commitment to patient-centered solutions, enhancing experiences for both patients and healthcare providers[20]. - The Medtronic Employee Emergency Assistance Fund has provided $4 million in grants over the last five years to employees facing financial hardships due to unexpected events[49]. - The company achieved 100% pay equity for gender and ethnically diverse employees in the U.S. and 99% globally for gender[43]. Future Outlook - The company announced plans to separate its Diabetes business, aiming to create a new independent, publicly traded company within 18 months of the announcement[38]. - The company intends to expand operations in emerging markets, which could expose it to additional risks and costs[149]. - Continued global adoption of the TYRX Envelope for implantable devices is expected to drive future growth in Cardiovascular[207].

Financial Performance - Revenues for Q3 fiscal 2025 were $17.7 billion, an increase of 8% in U.S. dollars and 7% in local currency compared to Q3 fiscal 2024[70] - New bookings for Q3 fiscal 2025 were $19.7 billion, a decrease of 6% in U.S. dollars and 7% in local currency[70] - Operating margin for Q3 fiscal 2025 was 16.8%, up from 16.0% in Q3 fiscal 2024[70] - Diluted earnings per share for Q3 fiscal 2025 were $3.49, a 15% increase from $3.04 in Q3 fiscal 2024[70] - Revenues for Q3 fiscal 2025 increased to $17.7 billion, an 8% increase compared to $16.5 billion in Q3 fiscal 2024[85] - Operating income for the third quarter of fiscal 2025 increased by $352 million, or 13%, compared to the same period in fiscal 2024, with an operating margin of 16.8%[101] - For the nine months ended May 31, 2025, operating income rose by $934 million, or 13%, with an operating margin of 15.7%[101] Shareholder Returns - Cash returned to shareholders in Q3 fiscal 2025 totaled $2.7 billion, including dividends of $924 million and share purchases of $1.8 billion[70] - During the nine months ended May 31, 2025, Accenture plc repurchased a total of 12,478,861 shares for $4,141 million, including 10,326,925 shares through open-market purchases valued at $3,381 million[122] - The company plans to continue utilizing a significant portion of cash generated from operations for share repurchases throughout the remainder of fiscal 2025, with the number of shares repurchased depending on various market conditions[124] Revenue Breakdown - Consulting revenues increased by 7% in U.S. dollars and 6% in local currency for Q3 fiscal 2025, driven by strong growth in the Americas and EMEA[74] - Managed services revenues increased by 9% in both U.S. dollars and local currency for Q3 fiscal 2025, supported by strong demand for application modernization and cloud enablement[75] - Revenues in the Americas increased by 8% in Q3 fiscal 2025, driven by growth in Public Service, Banking & Capital Markets, and Insurance[87] Cost and Expenses - Operating expenses for Q3 fiscal 2025 increased by $909 million, or 7%, totaling $14.7 billion, while decreasing as a percentage of revenues to 83.2% from 84.0%[90] - Cost of services for Q3 fiscal 2025 increased by $933 million, or 9%, and represented 67.1% of revenues, compared to 66.6% in Q3 fiscal 2024[93] - Sales and marketing expenses for Q3 fiscal 2025 increased by $12 million, or 1%, and decreased as a percentage of revenues to 9.9% from 10.6%[95] - General and administrative costs for Q3 fiscal 2025 increased by $42 million, or 4%, and decreased as a percentage of revenues to 6.1% from 6.3%[96] Workforce and Utilization - The workforce increased to approximately 791,000 as of May 31, 2025, compared to approximately 750,000 a year earlier, reflecting hiring for skills needed to support service demand[78] - Utilization rate for Q3 fiscal 2025 was 92%, consistent with the same quarter in fiscal 2024[78] - Annualized attrition rate for Q3 fiscal 2025 was 16%, up from 14% in Q3 fiscal 2024[79] Cash and Debt - As of May 31, 2025, cash and cash equivalents totaled $9.6 billion, up from $5.0 billion as of August 31, 2024[117] - Net cash provided by operating activities for the nine months ended May 31, 2025 was $7,560 million, an increase of $1,819 million from the prior year[117] - The net increase in cash and cash equivalents for the nine months ended May 31, 2025 was $4,627 million, a significant improvement from a decrease of $3,508 million in the prior year[117] - The company had outstanding long-term debt of $5 billion as of May 31, 2025, with maturities ranging from 2027 to 2034[120] Interest and Tax - Interest income for the third quarter of fiscal 2025 was $79 million, an increase of $25 million over the same quarter in fiscal 2024[108] - Interest expense for the third quarter of fiscal 2025 was $68 million, an increase of $56 million compared to the third quarter of fiscal 2024[109] - The effective tax rate for the third quarter of fiscal 2025 was 24.0%, down from 25.4% in the same quarter of fiscal 2024[111] Internal Controls and Risk Management - Accenture plc's management has evaluated the effectiveness of its disclosure controls and procedures, concluding they were effective at the reasonable assurance level as of the end of the reporting period[127] - There have been no changes in internal control over financial reporting that materially affected the company during the third quarter of fiscal 2025[128] - There were no material changes to market risk exposure during the nine months ended May 31, 2025, as disclosed in the Annual Report for the year ended August 31, 2024[126] - The company has not been required to make any significant payments under off-balance sheet arrangements to date[126] Share Repurchase Program - The share repurchase program may be accelerated, suspended, delayed, or discontinued at any time without notice, depending on various factors[124] - The company acquired shares primarily through share withholding for payroll tax obligations under employee equity share plans, which do not affect the aggregate available authorization for open-market purchases[123] - Accenture continues to monitor its capital allocation planning, cash and debt balances, and other cash demands, including acquisition activity[124]

Financial Performance - New bookings for Q3 FY25 were $19.7 billion, a decrease of 6% in U.S. dollars and 7% in local currency compared to Q3 FY24[8]. - Revenues for Q3 FY25 reached $17.73 billion, an increase of 8% in U.S. dollars and 7% in local currency[10]. - Operating margin for Q3 FY25 was 16.8%, an increase of 80 basis points compared to the previous year[19]. - Diluted earnings per share for Q3 FY25 were $3.49, a 15% increase from $3.04 in Q3 FY24[20]. - Free cash flow for Q3 FY25 was $3.5 billion, compared to $3.02 billion in Q3 FY24[21]. - The company expects full-year revenue growth to be between 6% and 7% in local currency[6]. - Generative AI new bookings amounted to $1.5 billion during the quarter[6]. - Revenues for the three months ended May 31, 2025, were $17,727,871, representing a 7.6% increase from $16,466,828 for the same period in 2024[37]. - Total revenues for the three months ended May 31, 2025, increased by 8% to $17,727,871 compared to $16,466,828 for the same period in 2024[39]. - Total revenues for the nine months ended May 31, 2025, were $52,076,717, an increase from $48,490,645 for the same period in 2024[37]. - Total revenues for the nine months ended May 31, 2025, were $52,076,717, representing a 7% increase from $48,490,645 in the prior year[39]. Income and Earnings - Operating income for the three months ended May 31, 2025, was $2,982,782, which is 16.8% of revenues, compared to 16.0% for the same period in 2024[37]. - Net income attributable to Accenture plc for the three months ended May 31, 2025, was $2,197,501, a 13.8% increase from $1,932,183 in the same period last year[37]. - Earnings per share (diluted) for the three months ended May 31, 2025, were $3.49, compared to $3.04 for the same period in 2024, reflecting a 14.8% increase[37]. - Net income for the three months ended May 31, 2025, was $2,243,963, an increase from $1,981,348 in the prior year[43]. - Diluted earnings per share for the three months ended May 31, 2025, increased to $3.49 from $3.04 in the same period last year[43]. Cash Flow and Dividends - The quarterly cash dividend was increased by 15% to $1.48 per share, totaling $924 million in payments[25]. - Accenture repurchased 6.0 million shares for a total of $1.8 billion during Q3 FY25[25]. - Cash dividends per share increased to $1.48 for the three months ended May 31, 2025, up from $1.29 in the same period last year[37]. - The company paid cash dividends of $2,778,444 thousand for the nine months ended May 31, 2025, compared to $2,433,610 thousand for the same period in 2024, an increase of approximately 14.2%[46]. - Net cash provided by operating activities for the nine months ended May 31, 2025, was $7,560,252 thousand, compared to $5,741,596 thousand for the same period in 2024, an increase of about 31.7%[46]. Assets and Liabilities - The total cash balance at May 31, 2025, was $9.6 billion, up from $5.0 billion at August 31, 2024[22]. - Total assets increased to $63,362,028 thousand as of May 31, 2025, up from $55,932,363 thousand on August 31, 2024, representing a growth of approximately 13.5%[45]. - Total current liabilities decreased slightly to $18,768,835 thousand from $18,976,127 thousand, a reduction of approximately 1.1%[45]. - Long-term debt increased significantly to $5,035,975 thousand from $78,628 thousand, indicating a substantial rise in leverage[45]. - The company reported a net cash used in investing activities of $(1,248,360) thousand for the nine months ended May 31, 2025, compared to $(5,514,644) thousand for the same period in 2024, showing a decrease in cash outflow by approximately 77.3%[46]. Sector Performance - The Americas region reported revenues of $8,966,131 for the three months ended May 31, 2025, an 8% increase from $8,286,527 in the same period last year[39]. - Financial Services sector revenues grew by 13% to $3,278,891 for the three months ended May 31, 2025, compared to $2,894,753 in the previous year[39]. - The Health & Public Service sector reported a 10% increase in revenues to $11,199,205 for the nine months ended May 31, 2025, compared to $10,226,769 in the previous year[39]. Economic Outlook - The company anticipates ongoing challenges related to economic and geopolitical conditions, which may impact future performance[35].

Financial Performance - Net sales for fiscal 2025 were $474.7 million, a decrease of $61.2 million, or 11.4%, compared to fiscal 2024[223] - Gross profit decreased by $30.9 million, or 19.6%, with a gross margin of 26.8%, down 270 basis points from the prior year[223] - Net income for fiscal 2025 was $13.4 million, or $0.30 per diluted share, compared to $41.4 million, or $0.89 per diluted share, in fiscal 2024[223] - Operating income decreased by $23.2 million, or 49.3%, to $23.9 million, representing 5.0% of net sales[234] - Net income for fiscal 2025 was $13.4 million, down $27.9 million or 67.5% compared to fiscal 2024, resulting in a diluted net income per share of $0.30[239] - Income tax expense for fiscal 2025 was $5.8 million, a decrease of $4.5 million or 43.8% from fiscal 2024, with an effective tax rate of 30.2%[238] Cash Flow and Investments - Cash used in operating activities was $7.2 million in fiscal 2025, a decline of $113.9 million from cash provided in fiscal 2024[240] - Cash used in investing activities decreased by $62.3 million in fiscal 2025, with capital expenditures of $21.6 million, $69.2 million lower than fiscal 2024[243] - Cash used in financing activities was $9.2 million in fiscal 2025, primarily due to $25.5 million in share repurchases and $23.1 million in dividend distributions[245] - The company expects to spend between $25.0 million and $30.0 million on capital expenditures in fiscal 2026[244] - The company had $25.2 million in cash and cash equivalents on hand as of April 30, 2025[250] Expenses and Costs - Research and development expenses increased by $2.3 million, or 31.8%, primarily due to higher materials and testing costs associated with new product development[232] - Interest expense increased by $2.6 million, or 124.9%, primarily due to higher average debt balances[236] - Inflationary pressures have increased costs for components, parts, raw materials, and labor, expected to continue impacting the company in fiscal 2026[253] Inventory and Sales - Inventory balances increased by $29.3 million between April 30, 2024, and April 30, 2025, due to a slowdown in demand[231] - New products accounted for 42.8% of net sales for the 12 months ended April 30, 2025, including six new pistols and six new long guns[229] Market Overview - The U.S. firearm manufacturing industry grew at a 1.5% compound annual growth rate in units from 2018 through 2023[225] - The annual domestic non-military firearm market is estimated at approximately $2.8 billion for handguns and $1.9 billion for long guns[225] Debt and Compliance - As of April 30, 2025, the company had $80.0 million of borrowings outstanding on its revolving line of credit, with an average interest rate of 6.69%[247] - The company is in compliance with all debt covenants as of April 30, 2025[247]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________to ____________ Commission file number: 001-41277 MODULAR MEDICAL, INC. (Exact name of registrant as specified in its charter) | Nevada | 87-0620495 | | - ...

Table of Contents Washington, D.C. 20549 Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from/to or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date o ...

Exhibit 99.2 CRESCENT BIOPHARMA, INC. CONDENSED BALANCE SHEETS (UNAUDITED) (in thousands except share and per share amounts) | | March 31, | | | December 31, | | --- | --- | --- | --- | --- | | | | 2025 | | 2024 | | Assets | | | | | | Current assets: | | | | | | Cash | $ | 22,429 | $ | 34,766 | | Prepaid expenses and other current assets | | 409 | | 38 | | Total current assets | | 22,838 | | 34,804 | | Other assets | | 2,767 | | 813 | | Total assets | $ | 25,605 | $ | 35,617 | | Liabilities, Convertible Pre ...

Revenues increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024 Expect to report revenue of at least $1.7 million for quarter ending June 30, 2025, and introducing revenue guidance of $12-$16 million for the full fiscal year 2026 Submitted PMA supplement for second-generation LungFit® PH to FDA Exhibit 99.1 Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update International distribution partnerships now provide acce ...

Exhibit 99.1 111 W 19 Street, 8 Floor New York, NY 10011 th th New Fortress Energy Completes Sale of Jamaica Assets & Operations to Excelerate Energy and Announces First Quarter 2025 Results May 14, 2025 NEW YORK -- New Fortress Energy Inc. (Nasdaq: NFE) ("NFE" or the "Company") today announced the completion of the sale of its assets and operations in Jamaica to Excelerate Energy, Inc. (NYSE: EE) ("Excelerate") for $1.055 billion. The transaction was initially announced by NFE on March 27, 2025. Proceeds f ...